Blog

Dr. William P. Murphy delivers Keynote Address at the Academy of Regenerative Practices

Sunrise, FL – February 9, 2016 – US STEM CELL, Inc. (OTCQB:USRM) – The chairman of the board of directors of US Stem Cell Inc, Dr. William P. Murphy, Jr., delivered the keynote address at the 2nd annual Academy of Regenerative Practices (www.regenerativeacademy.com) in Ft. Lauderdale, Florida this past weekend. A medical pioneer and founder of Cordis Corporation (now a Johnson & Johnson company), Dr Murphy is a medical doctor and inventor of medical devices including collaborating on a flexible sealed blood bag used for blood transfusions as well as patents for inventing the physiologic pace maker and the artificial kidney. He is the son of the American physician William Parry Murphy who shared the Nobel Prize in Physiology for Medicine in 1934, and Harriett Adams, the first licensed female dentist in Massachusetts.

U.S. Stem Cell Now Trading USRM; Completes Financing Transaction

Sunrise, FL – December 4, 2015 – US STEM CELL, Inc. (OTC: USRM) (f/k/a Bioheart, Inc.) a Florida corporation, a leader in the regenerative medicine, cellular therapy industry providing physician based stem cell therapies to human and animal patients as well as a developer of novel autologous cell therapies, is pleased to announce the completion of its name change with its new trading symbol – USRM. Additionally, the Company has completed a financing transaction with Magna Equities II, LLC (“Magna”).

U.S. Stem Cell Announces Positive Results for Traumatic Brain Injury (TBI) Patients

Sunrise, FL – December 3, 2015 – U.S. STEM CELL, Inc. (OTC: USRM), a Florida corporation, a leader in the regenerative medicine/cellular therapy industry, developer of novel autologous cell therapies, and provider of physician based stem cell therapies to human and animal patients, is pleased to announce that it has successfully completed five physician based treatments of traumatic brain injury (TBI) patients. The five patients, who received stromal vascular fraction from adipose tissue delivered intrathecally, have been treated over the past 12 months at the US Stem Cell Clinic located in Sunrise, FL

U.S. Stem Cell, Inc. Reports Positive Results for 3Q 2015

Sunrise, FL – November 5, 2015 – U.S. STEM CELL, Inc., a Florida corporation, (f/k/a/ Bioheart, Inc.) a leader in the regenerative medicine, cellular therapy industry providing physician based stem cell therapies to human and animal patients as well as a developer of novel autologous cell therapies, is pleased to highlight the following results from operations for the quarter ending September 30, 2015:

U.S. Stem Cell, Inc. (f/k/a/ Bioheart, Inc.) Receives FINRA Approval for Reverse Split and Name Change

Sunrise, FL – November 4, 2015 – U.S. STEM CELL, Inc., a Florida corporation, (f/k/a/ Bioheart, Inc.) a leader in the regenerative medicine, cellular therapy industry providing physician based stem cell therapies to human and animal patients as well as a developer of novel autologous cell therapies, is pleased to announce that it has received approval, effective today, from the Financial Industry Regulatory Authority (“FINRA”) to implement a reverse stock split in the ratio of 1 share for every 1,000 shares of its Common Stock. In connection with the Company’s reverse stock split, FINRA has assigned the Company a new stock symbol, BHRTD. The Company’s stock will be quoted as BHRTD through December 2, 2015, and thereafter, the trading symbol will be USRM (OTC Markets), reflecting the new name of the Company. The new CUSIP number is 90350U100. Additional information on the above transaction and name change can be found in our November 4, 2015 Form 8-K filing. Current stock certificates may be exchanged for new certificates by contacting the Company’s transfer agent, Continental Stock Transfer & Trust Company at:

US STEM CELL (Bioheart) Announces Insiders Intend to Purchase Company Common Stock in the Open Market

SUNRISE, FL / ACCESSWIRE / September 17, 2015 / US STEM CELL, Inc. (in transition from Bioheart, Inc. (BHRT.OB)) – announces today that “insiders” led by Dr. William P. Murphy, Jr., Chairman and Mike Tomas, President and CEO, intend to purchase, in the open market, up to 5% of the issued and outstanding Common Stock of the Company. The planned insider purchases are subject to customary restrictions based upon any of the participant’s knowledge of material non-public information and are further subject to federal securities disclosure rules. As the planed insider purchases are to be executed by individuals, US STEM CELL cannot guarantee the number of shares to be purchased or the time frame in which these shares will be bought in the open market.

For Immediate Release: Bioheart and Ascyrus Medical Execute Investment Agreement

Sunrise, FL – March 19, 2015 – Bioheart, Inc., a Florida Corporation (BHRT.OB) and Ascyrus Medical, LLC, a Florida Limited Liability Corporation are pleased to announce that they have entered into an investment agreement. The investment agreement provides for Bioheart to obtain a consolidating ownership stake in Ascyrus Medical upon the achievement of certain business milestones. Bioheart has through June 30, 2015 to meet its milestone obligations.